Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1603) 1603
Publication (181) 181
Book Review (30) 30
Book Chapter (14) 14
Book / eBook (5) 5
Conference Proceeding (2) 2
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1239) 1239
index medicus (765) 765
familial adenomatous polyposis (575) 575
oncology (557) 557
female (524) 524
male (501) 501
animals (463) 463
cancer (455) 455
colorectal cancer (398) 398
adenomatous polyposis coli (340) 340
adult (339) 339
tumors (295) 295
middle aged (292) 292
mutation (289) 289
mice (287) 287
gastroenterology & hepatology (250) 250
surgery (239) 239
adenomatous polyposis coli - genetics (234) 234
adenomatous polyposis coli - drug therapy (231) 231
colorectal-cancer (210) 210
genetic aspects (209) 209
cell biology (181) 181
beta-catenin (173) 173
aged (169) 169
colorectal neoplasms - genetics (167) 167
research (163) 163
apoptosis (162) 162
adenomatous polyposis coli protein - genetics (160) 160
adenomatous polyposis coli - pathology (159) 159
colon cancer (146) 146
signal transduction (142) 142
adenomatous polyposis coli - surgery (139) 139
care and treatment (138) 138
gene expression (137) 137
adolescent (136) 136
medicine & public health (136) 136
article (134) 134
expression (134) 134
chemoprevention (133) 133
risk factors (131) 131
biochemistry & molecular biology (130) 130
anti-inflammatory agents, non-steroidal - therapeutic use (129) 129
health aspects (124) 124
nonsteroidal antiinflammatory drugs (124) 124
colon (121) 121
treatment outcome (121) 121
colon-cancer (119) 119
sulindac (118) 118
analysis (116) 116
colorectal neoplasms - prevention & control (115) 115
chemotherapy (114) 114
prevention (114) 114
antineoplastic agents - therapeutic use (111) 111
colorectal neoplasms - pathology (111) 111
adenomatous polyposis coli - complications (110) 110
disease models, animal (109) 109
apc (108) 108
proteins (108) 108
medicine (107) 107
cell line, tumor (103) 103
genes, apc (102) 102
genes (100) 100
multidisciplinary sciences (100) 100
tumorigenesis (100) 100
development and progression (99) 99
mice, inbred c57bl (99) 99
colorectal neoplasms - drug therapy (97) 97
mutations (97) 97
prognosis (97) 97
genetics & heredity (94) 94
metastasis (94) 94
research article (93) 93
β-catenin (93) 93
colorectal carcinoma (92) 92
adenomatous polyposis-coli (91) 91
sulindac - therapeutic use (91) 91
gastroenterology (90) 90
carcinogenesis (89) 89
risk (88) 88
polyposis, familial (84) 84
microsatellite instability (83) 83
adenomatous polyposis coli protein - metabolism (82) 82
science (82) 82
kinases (81) 81
beta catenin - metabolism (80) 80
apc gene (79) 79
patients (79) 79
digestive system diseases (77) 77
antineoplastic agents - pharmacology (75) 75
apoptosis - drug effects (75) 75
pharmacology & pharmacy (75) 75
stem cells (75) 75
adenomatous polyposis (74) 74
cell proliferation (74) 74
gene expression regulation, neoplastic (74) 74
management (74) 74
genetics (73) 73
medical research (73) 73
inflammation (72) 72
wnt protein (70) 70
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1555) 1555
French (16) 16
Japanese (15) 15
German (11) 11
Spanish (5) 5
Chinese (4) 4
Dutch (3) 3
Hungarian (3) 3
Italian (3) 3
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial
by Samadder, N. Jewel and Neklason, Deborah W and Boucher, Kenneth M and Byrne, Kathryn R and Kanth, Priyanka and Samowitz, Wade and Jones, David and Tavtigian, Sean V and Done, Michelle W and Berry, Therese and Jasperson, Kory and Pappas, Lisa and Smith, Laurel and Sample, Danielle and Davis, Rian and Topham, Matthew K and Lynch, Patrick and Strait, Elena and McKinnon, Wendy and Burt, Randall W and Kuwada, Scott K
JAMA, ISSN 0098-7484, 03/2016, Volume 315, Issue 12, pp. 1266 - 1275
IMPORTANCE: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps and cancer. Surgical and endoscopic... 
CELL LUNG-CANCER | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ADENOCARCINOMA | RISK | CHEMOPREVENTION | LONG-TERM TREATMENT | CELECOXIB | EXPRESSION | CYCLOOXYGENASE-2 INHIBITOR | Erlotinib Hydrochloride - adverse effects | Humans | Middle Aged | Erlotinib Hydrochloride - administration & dosage | Sulindac - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Duodenal Neoplasms - genetics | Male | Antineoplastic Agents - therapeutic use | Adenomatous Polyposis Coli - pathology | Sulindac - adverse effects | Genes, APC | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Duodenal Neoplasms - drug therapy | Adenomatous Polyposis Coli - drug therapy | Adult | Female | Adenomatous Polyposis Coli - genetics | Duodenal Neoplasms - pathology | Treatment outcome | Erlotinib | Sulindac | Analysis | Dosage and administration | Polyposis, Familial | Drug therapy | Drugs | Clinical trials | Placebo effect | Risk factors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sulindac and Erlotinib for Familial Adenomatous Polyposis—Reply
by Samadder, N. Jewel and Neklason, Deborah W and Burt, Randall W
JAMA, ISSN 0098-7484, 08/2016, Volume 316, Issue 5, pp. 545 - 545
MEDICINE, GENERAL & INTERNAL | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Duodenal Neoplasms - drug therapy | Adenomatous Polyposis Coli - drug therapy | Humans | Female | Male | Antineoplastic Agents - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1
by Zhang, Huabing and Ramakrishnan, Sadeesh K and Triner, Daniel and Centofanti, Brook and Maitra, Dhiman and Gyorffy, Balázs and Sebolt-Leopold, Judith S and Dame, Michael K and Varani, James and Brenner, Dean E and Fearon, Eric R and Omary, M. Bishr and Shah, Yatrik M
Science Signaling, ISSN 1945-0877, 10/2015, Volume 8, Issue 397, pp. ra98 - ra98
Yes-associated protein 1 (YAP1) is a transcriptional coactivator in the Hippo signaling pathway. Increased YAP1 activity promotes the growth of tumors,... 
PHOTODYNAMIC THERAPY | PATHWAY | COLORECTAL-CANCER | BIOCHEMISTRY & MOLECULAR BIOLOGY | HIPPO | GROWTH | MACULAR DEGENERATION | CELL-PROLIFERATION | CHOROIDAL NEOVASCULARIZATION | TEAD/TEF FAMILY | TUMORIGENESIS | CELL BIOLOGY | Transcription, Genetic - drug effects | Phosphorylation | Adenocarcinoma - pathology | Molecular Weight | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Neoplasm Proteins - physiology | Colonic Neoplasms - chemically induced | Neoplasm Proteins - antagonists & inhibitors | Phosphoproteins - antagonists & inhibitors | Adenomatous Polyposis Coli - pathology | Autophagy - drug effects | Genes, APC | Neoplasm Proteins - drug effects | Proteasome Endopeptidase Complex - drug effects | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Adenoma - drug therapy | HEK293 Cells | Antineoplastic Agents - pharmacology | Phosphoproteins - physiology | Adenomatous Polyposis Coli - genetics | Mice, Inbred C57BL | Transcription Factors - antagonists & inhibitors | Porphyrins - pharmacology | Adenocarcinoma - drug therapy | Cell Division - drug effects | Mice, Knockout | Xenograft Model Antitumor Assays | Adaptor Proteins, Signal Transducing - physiology | Animals | Adenomatous Polyposis Coli - drug therapy | Colonic Neoplasms - pathology | Adenoma - pathology | Cell Line, Tumor | Mice | Protein Processing, Post-Translational | STAT3 Transcription Factor - antagonists & inhibitors | Protein Multimerization - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis
by Cruz–Correa, Marcia and Shoskes, Daniel A and Sanchez, Patricia and Zhao, Rhongua and Hylind, Linda M and Wexner, Steven D and Giardiello, Francis M
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2006, Volume 4, Issue 8, pp. 1035 - 1038
Familialadenomatous polyposis (FAP) is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual... 
COLON-CANCER | CELLS | PROTEIN | CHEMOPREVENTIVE AGENT | SULINDAC | GASTROENTEROLOGY & HEPATOLOGY | I CLINICAL-TRIAL | EXPRESSION | TUMORS | RUTIN | Sigmoidoscopy | Curcumin - therapeutic use | Quercetin - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Adenomatous Polyposis Coli - pathology | Antioxidants - therapeutic use | Adenomatous Polyposis Coli - drug therapy | Adult | Female | Drug Therapy, Combination | Medical colleges | COX-2 inhibitors | Care and treatment | Colorectal cancer | Transplantation of organs, tissues, etc | Cytogenetics | Polyposis, Familial | Genetic aspects | Patient compliance | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis
by Cruz-Correa, Marcia and Hylind, Linda M and Marrero, Jessica Hernandez and Zahurak, Marianna L and Murray-Stewart, Tracy and Casero, Robert A and Montgomery, Elizabeth A and Iacobuzio-Donahue, Christine and Brosens, Lodewijk A and Offerhaus, G. Johan and Umar, Asad and Rodriguez, Luz M and Giardiello, Francis M
Gastroenterology, ISSN 0016-5085, 09/2018, Volume 155, Issue 3, pp. 668 - 673
Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal... 
Turmeric | Herbal | Familial Adenomatous Polyposis | Cancer Prevention | Gastroenterology | FAP | GENES | CHROMOSOME-5Q21 | MUTATIONS | IDENTIFICATION | GASTROENTEROLOGY & HEPATOLOGY | LOCUS | Double-Blind Method | Humans | Middle Aged | Adenoma - etiology | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Curcumin - administration & dosage | Young Adult | Adenomatous Polyposis Coli - complications | Colorectal Neoplasms - etiology | Adenomatous Polyposis Coli - drug therapy | Colorectal Neoplasms - drug therapy | Adenoma - drug therapy | Adolescent | Aged, 80 and over | Adult | Female | Aged | Prevention | Care and treatment | Polyposis, Familial | Genetic aspects | Colorectal cancer | Cancer | turmeric | herbal | cancer prevention
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis
by Narayan, Satya and Sharma, Ritika
Life Sciences, ISSN 0024-3205, 10/2015, Volume 139, pp. 145 - 152
Colorectal cancer (CRC) is the third leading cause of death in both men and women in North America. Despite chemotherapeutic efforts, CRC is associated with a... 
Colorectal carcinogenesis | Base excision repair | DNA damage | Adenomatous polyposis coli | CANCER-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | BREAST EPITHELIAL-CELLS | LONG-PATCH | NUCLEAR ANTIGEN | MISMATCH REPAIR | DNA-POLYMERASE-BETA | APC TUMOR-SUPPRESSOR | ALKYLATING-AGENTS | APURINIC APYRIMIDINIC SITES | PHARMACOLOGY & PHARMACY | STRAND DISPLACEMENT SYNTHESIS | Dacarbazine - therapeutic use | Rectum - pathology | Humans | Colon - drug effects | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Adenomatous Polyposis Coli - pathology | Carcinogenesis - metabolism | Adenomatous Polyposis Coli Protein - analysis | Rectum - drug effects | Dacarbazine - analogs & derivatives | DNA Polymerase beta - metabolism | Adenomatous Polyposis Coli - genetics | Adenomatous Polyposis Coli Protein - genetics | DNA Repair - drug effects | Colon - pathology | Rectum - metabolism | Carcinogenesis - genetics | Models, Molecular | Flap Endonucleases - analysis | Flap Endonucleases - metabolism | Colon - metabolism | Adenomatous Polyposis Coli - metabolism | Carcinogenesis - drug effects | Carcinogenesis - pathology | DNA Polymerase beta - analysis | Animals | Adenomatous Polyposis Coli - drug therapy | Adenomatous Polyposis Coli Protein - metabolism | Mutation | Chemotherapy | Colon cancer | Mortality | Development and progression | Polyposis, Familial | Carcinogenesis | Cancer | Index Medicus | base excision repair | colorectal carcinogenesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling
by Zhang, Junfang and Cao, Hailong and Zhang, Bing and Cao, Hanwei and Xu, Xiuqin and Ruan, Hang and Yi, Tingting and Tan, Li and Qu, Rui and Song, Gang and Wang, Bangmao and Hu, Tianhui
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 11/2013, Volume 17, Issue 11, pp. 1484 - 1493
As a traditional anti‐inflammatory Chinese herbal medicine, Alkaloid berberine has been recently reported to exhibit anti‐tumour effects against a wide... 
Wnt | familial adenomatous polyposis | signal transduction | colon cancer | berberine | Berberine | Signal transduction | Colon cancer | Familial adenomatous polyposis | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | STEM-CELLS | CYCLOOXYGENASE-2 | CELL-GROWTH | BETA-CATENIN | HUMAN COLORECTAL-CANCER | CELL BIOLOGY | CARCINOGENESIS | PATHWAY | RECEPTORS | TUMORIGENESIS | Cell Proliferation | Humans | Mice, Inbred C57BL | Male | Mice, Transgenic | Adenomatous Polyposis Coli - pathology | beta Catenin - metabolism | Protein Transport | Up-Regulation - drug effects | Young Adult | Berberine - pharmacology | Animals | Wnt Signaling Pathway - drug effects | Adenomatous Polyposis Coli - drug therapy | Adenomatous Polyposis Coli Protein - metabolism | Adolescent | Cell Line, Tumor | Adult | Female | Mice | Berberine - therapeutic use | Anticarcinogenic Agents - pharmacology | Anticarcinogenic Agents - therapeutic use | Drug Screening Assays, Antitumor | Polyps (Pathology) | Polyposis, Familial | Genetic aspects | Analysis | Phosphorylation | Wnt protein | Genes | Colorectal cancer | Clinical trials | Myc protein | Cyclin D1 | Kinases | Polyposis coli | Proteins | Cell growth | Intestine | Tumor necrosis factor-TNF | Colon | Inhibition | Catenin | Adenomatous polyposis coli protein | Immunoglobulins | Oral administration | Inflammation | Grants | Gene expression | Patients | Adenomatous polyposis coli | Studies | Herbal medicine | Signaling | Polyps | Cancer | Tumors | Apoptosis | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Familial Adenomatous Polyposis; Succesful Use of Sirolimus
by Yuksekkaya, Hasan and Yucel, Aylin and Gumus, Meltem and Esen, Hasan and Toy, Hatice
American Journal of Gastroenterology, ISSN 0002-9270, 07/2016, Volume 111, Issue 7, pp. 1040 - 1041
Sirolimus - therapeutic use | Colonic Polyps - pathology | Humans | Male | Treatment Outcome | Adenomatous Polyposis Coli - pathology | Intestinal Polyps - drug therapy | Antibiotics, Antineoplastic - therapeutic use | Duodenal Neoplasms - drug therapy | Adenomatous Polyposis Coli - drug therapy | Colonoscopy | Adolescent | Intestinal Polyps - pathology | Colonic Polyps - drug therapy | Endoscopy, Digestive System | Duodenal Neoplasms - pathology
Journal Article
Details down arrow
9. Full Text The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
by Steinbach, Gideon and Lynch, Patrick M and Phillips, Robin K.S and Wallace, Marina H and Hawk, Ernest and Gordon, Gary B and Wakabayashi, Naoki and Saunders, Brian and Shen, Yu and Fujimura, Takashi and Su, Li-Kuo and Levin, Bernard and Godio, Louis and Patterson, Sherri and Rodriguez-Bigas, Miguel A and Jester, Susan L and King, Karen L and Schumacher, Marta and Abbruzzese, James and DuBois, Raymond N and Hittelman, Walter N and Zimmerman, Stuart and Sherman, Jeffrey W and Kelloff, Gary
The New England Journal of Medicine, ISSN 0028-4793, 06/2000, Volume 342, Issue 26, pp. 1946 - 1952
Human colon cancer develops in a stepwise fashion from normal mucosa to adenomatous polyps to carcinoma. Mutation in the adenomatous polyposis coli ( APC )... 
RHEUMATOID-ARTHRITIS | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | INDUCED COLON CARCINOGENESIS | COLORECTAL-CANCER | ASPIRIN USE | RATS | SULINDAC THERAPY | RISK | EXPRESSION | RECTAL ADENOMAS | Double-Blind Method | Prostaglandin-Endoperoxide Synthases - pharmacology | Pyrazoles | Cyclooxygenase 2 | Humans | Male | Celecoxib | Dose-Response Relationship, Drug | Membrane Proteins | Cyclooxygenase 2 Inhibitors | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adenomatous Polyposis Coli - drug therapy | Isoenzymes - pharmacology | Sulfonamides - adverse effects | Adult | Female | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Isoenzymes - antagonists & inhibitors | Prevention | Evaluation | Colorectal cancer | Polyposis, Familial | Intestinal polyps | Drug therapy | Rodents | Mortality | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Sulindac and Erlotinib for Familial Adenomatous Polyposis
by Matuchansky, Claude
JAMA, ISSN 0098-7484, 08/2016, Volume 316, Issue 5, pp. 544 - 545
DUODENAL POLYPS | MEDICINE, GENERAL & INTERNAL | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Duodenal Neoplasms - drug therapy | Adenomatous Polyposis Coli - drug therapy | Humans | Female | Male | Antineoplastic Agents - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Chemoprevention in familial adenomatous polyposis
by Kim, Brian, MD and Giardiello, Francis M., MD
Best Practice & Research: Clinical Gastroenterology, ISSN 1521-6918, 2011, Volume 25, Issue 4, pp. 607 - 622
Familial adenomatous polyposis (FAP) predictably leads to adenomas and eventual adenocarcinomas in the lower gastrointestinal tract and less frequently, the... 
Gastroenterology and Hepatology | Familial adenomatous polyposis | Chemoprevention | Sulindac | Curcumin | Adenomas | Celecoxib | Eicosapentaenoic acid | COLORECTAL-CANCER RISK | INTESTINAL CARCINOGENESIS | RANDOMIZED-TRIAL | DIFLUOROMETHYLORNITHINE PLUS SULINDAC | SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | RECTAL POLYPS | DOUBLE-BLIND | POLYUNSATURATED FATTY-ACIDS | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | LONG-TERM TREATMENT | Genetic Predisposition to Disease | Risk Assessment | Colorectal Neoplasms - genetics | Humans | Risk Factors | Adenomatous Polyposis Coli - surgery | Colorectal Neoplasms - prevention & control | Treatment Outcome | Colectomy | Disease Progression | Animals | Adenomatous Polyposis Coli - drug therapy | Adenomatous Polyposis Coli - genetics | Anticarcinogenic Agents - therapeutic use | Prevention | Hydrochloric acid | COX-2 inhibitors | Gastrointestinal system | Polyposis, Familial | Genetic aspects | Omega-3 fatty acids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis
by Li, Bin and Flaveny, Colin A and Giambelli, Camilla and Liang Fei, Dennis and Han, Lu and Hang, Brian I and Bai, Feng and Pei, Xin-Hai and Nose, Vania and Burlingame, Oname and Capobianco, Anthony J and Orton, Darren and Lee, Ethan and Robbins, David J
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e101969
Mutations in the WNT-pathway regulator ADENOMATOUS POLYPOSIS COLI (APC) promote aberrant activation of the WNT pathway that is responsible for APC-associated... 
MURINE MODEL | CYCLIN D1 | PHOSPHORYLATION | COLORECTAL-CANCER | APC GENE | MULTIDISCIPLINARY SCIENCES | DOWN-REGULATION | COLON | E-CADHERIN | BETA-CATENIN | ADENOMATOUS POLYPOSIS | Cell Survival - drug effects | HCT116 Cells | Humans | Mice, Inbred C57BL | Mice, Transgenic | Drug Approval | Drug Repositioning | Animals | Wnt Signaling Pathway - drug effects | Adenomatous Polyposis Coli - drug therapy | Antineoplastic Agents - pharmacology | Pyrvinium Compounds - pharmacology | Drug Screening Assays, Antitumor | Drugs | Chemotherapy | Drug approval | Colorectal cancer | Cancer | Wnt protein | Familial adenomatous polyposis | Oncology | Activation | Adenoma | Kinases | Polyposis coli | Cancer therapies | Proteins | Intestine | Surgery | Bioindicators | Pharmaceutical industry | Developmental biology | Oral administration | Breast cancer | FDA approval | Gene expression | Adenomatous polyposis coli | Pathology | Signaling | Stem cells | Biomarkers | Mice | Mutation | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model
<